SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT01259050

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Phase 1 Open Label Study of Zinc Therapy in ALS Patients

The purpose of this study is to determine the safety of Zinc given at 90mg/d in conjunction with 2mg/d of copper in ALS patients.

NCT01259050 Amyotrophic Lateral Sclerosis
MeSH: Motor Neuron Disease Amyotrophic Lateral Sclerosis
HPO: Abnormal anterior horn cell morphology Amyotrophic lateral sclerosis

1 Interventions

Name: Zinc and Copper

Description: Optizinc 90 mg/d Copper 1 mg

Type: Drug

Zinc and Copper


Primary Outcomes

Measure: To evaluate the safety of high doses of zinc in patients with ALS

Time: 1 year

Secondary Outcomes

Measure: Measure levels of BMAA in blood and urine to determine if there is a decline in these levels over the course of treatment

Time: 1 year

Purpose: Treatment

Allocation: Randomized

Single Group Assignment


There is one SNP

SNPs


1 G93A

Previous studies have shown that in ALS mutant G93A SOD transgenic mice, actual zinc supplementation delayed death. --- G93A ---



HPO Nodes


HPO:
Abnormal anterior horn cell morphology
Genes 18
ASAH1 TFG CPLANE1 CEP126 DCTN1 IGHMBP2 PRPH SMN1 SMN2 VRK1 SMN1 ATXN3 UBA1 SOD1 SMN1 NEFH SETX GLE1
Amyotrophic lateral sclerosis
Genes 77
MATR3 TREM2 VCP FUS PRPH ANXA11 ALS2 C9ORF72 HNRNPA1 PRPH PFN1 FUS UBQLN2 SQSTM1 ATXN2 MATR3 TBK1 CHMP2B SIGMAR1 PON1 OPTN MAPT MATR3 ANG VCP DAO ERBB4 SQSTM1 SPG11 NEFH EPHA4 CCNF ANG TARDBP DCTN1 PON2 SOD1 ANXA11 UBQLN2 GLT8D1 FIG4 OPTN DCTN1 TARDBP CHMP2B VAPB SIGMAR1 HNRNPA1 CFAP410 PFN1 PSEN1 HNRNPA1 SOD1 SPG11 C9ORF72 ALS2 TRPM7 ERBB4 CHCHD10 KIF5A VAPB PON3 FIG4 GLE1 NEK1 CHCHD10 PPARGC1A TUBA4A VCP UNC13A TBK1 VCP HNRNPA2B1 TAF15 FUS NEFH SETX